Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,308 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase II trial of anastrozole in women with asymptomatic müllerian cancer.
del Carmen MG, Fuller AF, Matulonis U, Horick NK, Goodman A, Duska LR, Penson R, Campos S, Roche M, Seiden MV. del Carmen MG, et al. Among authors: roche m. Gynecol Oncol. 2003 Dec;91(3):596-602. doi: 10.1016/j.ygyno.2003.08.021. Gynecol Oncol. 2003. PMID: 14675683 Clinical Trial.
A phase II trial of three sequential doublets for the treatment of advanced müllerian malignancies.
Matulonis U, Campos S, Duska L, Fuller A, Berkowitz R, Gore S, Roche M, Colella T, Lee H, Seiden MV; Gynecologic Oncology Research Program at Dana Farber/Partners Cancer Care; Dana Farber-Harvard Cancer Care. Matulonis U, et al. Among authors: roche m. Gynecol Oncol. 2003 Nov;91(2):293-8. doi: 10.1016/s0090-8258(03)00496-7. Gynecol Oncol. 2003. PMID: 14599858 Clinical Trial.
Three sequential chemotherapy doublets for the treatment of newly diagnosed advanced müllerian malignancies: the modified triple doublet regimen.
Matulonis UA, Campos S, Krasner CN, Duska LR, Penson RT, Falke R, Roche M, Smith LM, Lee H, Seiden MV; Dana-Farber/Partners CancerCare and Harvard Vanguard Medical Associates. Matulonis UA, et al. Among authors: roche m. Gynecol Oncol. 2006 Nov;103(2):575-80. doi: 10.1016/j.ygyno.2006.04.017. Epub 2006 Jun 23. Gynecol Oncol. 2006. PMID: 16806439 Clinical Trial.
Final report on serial phase II trials of all-intraperitoneal chemotherapy with or without bevacizumab for women with newly diagnosed, optimally cytoreduced carcinoma of Müllerian origin.
Krasner CN, Castro C, Penson RT, Roche M, Matulonis UA, Morgan MA, Drescher C, Armstrong DK, Wolfe JK, Lee H, Supko JG, Seiden M, Birrer MJ, Dizon DS. Krasner CN, et al. Among authors: roche m. Gynecol Oncol. 2019 May;153(2):223-229. doi: 10.1016/j.ygyno.2019.02.004. Epub 2019 Feb 12. Gynecol Oncol. 2019. PMID: 30765148 Clinical Trial.
1,308 results